PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	aldo-keto reductase family 1 member C1	Homo sapiens	51-57	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	aldo-keto reductase family 1 member C3	Homo sapiens	59-65	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	aldo-keto reductase family 1 member B1	Ictalurus punctatus	67-73	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	aldo-keto reductase family 1 member B10	Homo sapiens	79-86	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	Bortezomib	33-43	aldo-keto reductase family 1 member C1	Homo sapiens	51-57	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	Bortezomib	33-43	aldo-keto reductase family 1 member C3	Homo sapiens	59-65	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	Bortezomib	33-43	aldo-keto reductase family 1 member B1	Ictalurus punctatus	67-73	
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	Bortezomib	33-43	aldo-keto reductase family 1 member B10	Homo sapiens	79-86	
21215737-3	2011	Proteasome inhibitors bortezomib and MG-132 produce mild oxidative stress that activates Nrf2-mediated gene expression that in turn may have cytoprotective effects.	Bortezomib	22-32	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93	
21215737-3	2011	Proteasome inhibitors bortezomib and MG-132 produce mild oxidative stress that activates Nrf2-mediated gene expression that in turn may have cytoprotective effects.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	37-43	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	Bortezomib	45-55	aldo-keto reductase family 1 member C1	Homo sapiens	88-94	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	Bortezomib	45-55	aldo-keto reductase family 1 member B1	Ictalurus punctatus	100-106	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	Bortezomib	45-55	aldo-keto reductase family 1 member B10	Homo sapiens	112-119	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	60-66	aldo-keto reductase family 1 member C1	Homo sapiens	88-94	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	60-66	aldo-keto reductase family 1 member B1	Ictalurus punctatus	100-106	
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	60-66	aldo-keto reductase family 1 member B10	Homo sapiens	112-119	
21215737-9	2011	In SW-480 cells, treatment with bortezomib (50 nM, 48 h) dramatically increased mRNA levels of AKR1B10 (32-fold), AKR1B1 (5.5-fold), and, to a lesser extent, AKR1C1 and AKR1C3.	Bortezomib	32-42	aldo-keto reductase family 1 member B10	Homo sapiens	95-102	
21215737-9	2011	In SW-480 cells, treatment with bortezomib (50 nM, 48 h) dramatically increased mRNA levels of AKR1B10 (32-fold), AKR1B1 (5.5-fold), and, to a lesser extent, AKR1C1 and AKR1C3.	Bortezomib	32-42	aldo-keto reductase family 1 member B	Homo sapiens	95-101	
21215737-9	2011	In SW-480 cells, treatment with bortezomib (50 nM, 48 h) dramatically increased mRNA levels of AKR1B10 (32-fold), AKR1B1 (5.5-fold), and, to a lesser extent, AKR1C1 and AKR1C3.	Bortezomib	32-42	aldo-keto reductase family 1 member C1	Homo sapiens	158-164	
21215737-9	2011	In SW-480 cells, treatment with bortezomib (50 nM, 48 h) dramatically increased mRNA levels of AKR1B10 (32-fold), AKR1B1 (5.5-fold), and, to a lesser extent, AKR1C1 and AKR1C3.	Bortezomib	32-42	aldo-keto reductase family 1 member C3	Homo sapiens	169-175	
21215737-12	2011	MG-132 increased mRNA amounts of AKR1C1, 1C3, 1B1, and 1B10 in a concentration-dependent manner.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-6	aldo-keto reductase family 1 member C1	Homo sapiens	33-39	
21215737-13	2011	AKR1B10 and AKR1B1 protein expression was inducible by bortezomib in HT-29 cells, but not detectable in SW-480 cells.	Bortezomib	55-65	aldo-keto reductase family 1 member B10	Homo sapiens	0-7	
21215737-13	2011	AKR1B10 and AKR1B1 protein expression was inducible by bortezomib in HT-29 cells, but not detectable in SW-480 cells.	Bortezomib	55-65	aldo-keto reductase family 1 member B	Homo sapiens	0-6